Company research
Enveric Biosciences, Inc.
CIK 890821Updated Sep 29, 2026
SecurityENVB · NASDAQ · equity
Historical securities (1)
AMRHW · NASDAQ · warrant · closed Dec 31, 2020Name history
AMERI Holdings, Inc. · through Dec 30, 2020SPATIALIZER AUDIO LABORATORIES INC · through May 27, 2015
ENVB price & chart
Loading TradingView…
NASDAQ:ENVB on TradingView ↗About the company
We are a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, we are advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Our lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A filing
SCHEDULE 13G filing
SCHEDULE 13G/A filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
424B5 filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,095,941Source | 3,082,543Source | 4,299,840Source | 19,552,925Source |
| Property, Plant and Equipment, NetUSD | 159,234Source | 305,777Source | 507,377Source | 677,485Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 210,932Source | 379,686Source |
| Current assets: | ||||
| Assets, CurrentUSD | 4,936,707Source | 2,734,584Source | 3,581,531Source | 18,431,937Source |
| Prepaid Expense and Other Assets, CurrentUSD | 259,216Source | 493,558Source | 1,293,554Source | 708,053Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 63,817Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | — | — | — | 3,995,973Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 10,615Source | 6,780Source | 27,392Source | 20,782Source |
| Additional Paid in CapitalUSD | 119,593,456Source | 108,255,049Source | 100,815,851Source | 94,395,662Source |
| Retained Earnings (Accumulated Deficit)USD | -114,846,492Source | -106,074,505Source | -96,499,518Source | -79,207,786Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -580,038Source | -594,517Source | -569,749Source | -536,734Source |
| Stockholders' Equity Attributable to ParentUSD | 4,177,541Source | 1,592,807Source | 1,956,336Source | 14,671,924Source |
| Liabilities and EquityUSD | 5,095,941Source | 3,082,543Source | 4,299,840Source | 19,552,925Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 918,400Source | 1,489,736Source | 2,343,504Source | 3,995,973Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 63,820Source |
| Accounts Payable, CurrentUSD | 581,020Source | 521,747Source | 1,218,783Source | 463,275Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 237,505Source | 732,010Source | 1,075,643Source | 1,705,655Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | — | — | — | 885,028Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 827,323Source | 1,562,392Source | 2,150,160Source | 2,620,671Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 1,486,060Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,141,543Source | -7,726,139Source | -14,094,411Source | -17,146,723Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 11,667Source | -584,165Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 5,180Source | 584,165Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,579,507Source | 7,673,834Source | -1,343,141Source | 18,180,137Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,436,465Source | -46,951Source | -15,435,907Source | 367,885Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 5,249Source |
| Income Taxes Paid, NetUSD | — | 5,000Source | 9,507Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 647,435Source | 1,475,947Source | 1,994,085Source | 2,416,266Source |
| Amortization of Intangible AssetsUSD | 42,182Source | 168,750Source | 168,754Source | 168,750Source |
| DepreciationUSD | 158,676Source | 168,739Source | 175,228Source | 159,160Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 727,000Source | -325,000Source |
| Gain (Loss) on InvestmentsUSD | 1,707Source | 21,620Source | 208,752Source | 3,472,726Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 4,206Source | — |
| General and Administrative ExpenseUSD | 5,792,573Source | 6,453,505Source | 8,852,021Source | 11,605,761Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 7,453,662Source |
| Goodwill, Impairment LossUSD | — | — | — | 1,486,060Source |
| Income Tax Expense (Benefit)USD | — | 8,930Source | 28,913Source | -1,486,060Source |
| Net Income (Loss) Attributable to ParentUSD | -8,771,987Source | -9,574,987Source | -17,291,732Source | -18,471,333Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,131,472Source | -9,574,987Source | -17,458,761Source | -18,800,323Source |
| Nonoperating Income (Expense)USD | 2,461Source | 66,209Source | -814,379Source | 7,457,713Source |
| Operating Costs and ExpensesUSD | 8,774,448Source | 9,632,266Source | 16,448,440Source | 27,415,106Source |
| Proceeds from Issuance of Common StockUSD | — | 2,290,186Source | — | 17,222,099Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | 958,038Source |
| Restructuring CostsUSD | — | — | -572,628Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -8,774,448Source | -9,632,266Source | -16,448,440Source | -27,415,106Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,771,987Source | -9,566,057Source | -17,262,819Source | -19,957,393Source |
| Income Tax Expense (Benefit)USD | — | 8,930Source | 28,913Source | -1,486,060Source |
| Net Income (Loss) Attributable to ParentUSD | -8,771,987Source | -9,574,987Source | -17,291,732Source | -18,471,333Source |
| Earnings Per Share, BasicUSD per share | -36.24Source | -19.04Source | -8.09Source | -13Source |
| Earnings Per Share, DilutedUSD per share | -36.24Source | -19.04Source | -8.09Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 334,719Source | 502,900Source | 2,159,063Source | 1,446,007Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 334,719Source | 502,900Source | 2,159,063Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 42,182Source | 168,750Source | 168,754Source | 168,750Source |
| Current Income Tax Expense (Benefit)USD | — | 8,930Source | 28,913Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 200,858Source | 337,489Source | 343,982Source | 327,910Source |
| Gain (Loss) on InvestmentsUSD | 1,707Source | 21,620Source | 208,752Source | 3,472,726Source |
| General and Administrative ExpenseUSD | 5,792,573Source | 6,453,505Source | 8,852,021Source | 11,605,761Source |
| Goodwill, Impairment LossUSD | — | — | — | 1,486,060Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -7,463,931Source | -7,465,630Source | -10,205,116Source | -7,251,228Source |
| Interest ExpenseUSD | — | — | — | 5,249Source |
| Interest Income (Expense), NetUSD | -106Source | 219Source | 3,708Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,131,472Source | -9,574,987Source | -17,458,761Source | -18,800,323Source |
| Nonoperating Income (Expense)USD | 2,461Source | 66,209Source | -814,379Source | 7,457,713Source |
| Operating Costs and ExpensesUSD | 8,774,448Source | 9,632,266Source | 16,448,440Source | 27,415,106Source |
| Other IncomeUSD | 2,567Source | 20,000Source | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | 3,359,485Source | — | 19,041Source | 33,014Source |
| Research and Development ExpenseUSD | 2,781,017Source | 2,841,272Source | 7,252,437Source | 8,027,773Source |
| Restructuring CostsUSD | — | — | -572,628Source | — |
Offerings
Registration 333-293327
Underwriters: Forfeited, Vested
Registration 333-284277
- Gross proceeds
- 4999954.27
- Net proceeds
- 4649954.41
- Deal price
- 3.0
- Shares
- 1666651
- Offering price
- $3.00
- Ticker
- ENVB
Filing attachments
ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensiti…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolyti…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 April 30, 2026 Dear Enveric Biosciences, Inc. Stockholder, We are writing to inform you of an important update regarding our 2026 Annual Meeting of Stockholders. After the distribution of our definitive proxy statement, dated April 14, 2026, we identified a typographical error. To ensure you have the most accurate and complete information, we have filed additional definitive proxy materials with the Securities and Exchange Commission and are prov…
Read attachment ↗ex4-1.htm · 8-K · 2026-04-20
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 EXHIBIT A-2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗ex4-2.htm · 8-K · 2026-04-20
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗